Table 4 Changes in parameters related to the metabolic syndrome and females sex hormones in premenopausal BC patients during adjuvant anticancer treatment

Weight (kg)^a

73.3 ± 9.56

74.3 ± 9.31

74.7 ± 10.7

0.1

BMI (kg/m²)^b

25.7 [22.5; 29.0]

25.4 [23.0; 29.1]

25.2 [23.0; 29.2]

0.1

Waist (cm)^{a, g}

84.0 ± 6.07

85.5 ± 6.11

87.7 ± 7.91

0.2

Body fat (%)^a

34.1 ± 7.00

35.0 ± 7.48

36.7 ± 5.87

0.06

Lean body mass (kg)^a

44.8 ± 4.93

45.1 ± 5.01

43.9 ± 4.45

0.4

Bone mineral density (g/cm²)

1.17 ± 0.05

1.16 ± 0.06

1.15 ± 0.05

0.5

Total cholesterol (mmol/L)

5.22 ± 0.94

5.51 ± 1.28

5.22 ± 1.01

0.3

LDL (mmol/L)^a

2.93 ± 0.96

3.44 ± 1.18

2.77 ± 0.87

0.06

HDL (mmol/L)^a

1.78 ± 0.47

1.42 ± 0.43

1.76 ± 0.49

0.003 ^e

Triglyceride (mmol/L)^b

1.10 [0.88; 1.3]

1.20 [1.0; 1.76]

1.20 [0.80; 2.10]

0.05 ^e

Glucose (mmol/L)^a

5.50 ± 0.47

5.49 ± 0.57

5.28 ± 0.41

1.0

Insulin (pmol/L)^b

36.5 [25.8; 51.6]

43.5 [30.3; 62.5]

36.7 [27.3; 49.1]

0.05 ^e

HOMA-IR

0.72 [0.52; 1.0]

0.85 [0.60; 1.20]

0.70 [0.53; 0.94]

0.06

HOMAβ

62.6 [53.4; 73.5]

70.4 [60.0; 82.7]

67.2 [57.5; 78.7]

0.08

HbA1c (mmol/mol)^a

35.3 ± 4.15

Not relevant^f

35.3 ± 3.73

Not relevant^f

Systolic blood pressure mmHg^h

112 ± 11.8

115 ± 11.2

116 ± 9.16

0.3

Diastolic blood pressure mmHg^h

71.0 ± 8.47

72.3 ± 8.88

74.3 ± 7.01

0.3

Hs-CRP (mg/L)^b

1.04 [0.68; 2.45]

1.94 [0.96; 3.15]

1.21 [0.64; 2.15]

0.08

CD163 (mg/L)

1.66 [1.27; 2.10]

2.33 [1.58; 2.69]

1.71 [1.40; 2.22]

0.3 ^e

CD206 (mg/L)

0.21 [0.17; 0.25]

0.23 [0.20; 0.32]

0.23 [0.20; 0.28]

0.007 ^e

MetSⁱ

0 (0%)

0 (0%)

2 (15%)

1.0

FSH (IU/L)

3.9 [3.0; 22.1]

68 [50.4; 93.8]

39 [24.2; 50.3]

0.002 ^e

LH (IU/L)

4.7 [3.0; 36.1]

41 [36.2; 54.2]

25 [16.3; 28.8]

0.004 ^e

Estradiol (pmol/L)

471 [124; 752]

15 [15; 25.5]

27 [15; 252]

0.002 ^e